BE896383A - Procede pour stabiliser un facteur de necrose tumorale et solution aqueuse ou poudre stables contenant ce facteur - Google Patents
Procede pour stabiliser un facteur de necrose tumorale et solution aqueuse ou poudre stables contenant ce facteur Download PDFInfo
- Publication number
- BE896383A BE896383A BE0/210494A BE210494A BE896383A BE 896383 A BE896383 A BE 896383A BE 0/210494 A BE0/210494 A BE 0/210494A BE 210494 A BE210494 A BE 210494A BE 896383 A BE896383 A BE 896383A
- Authority
- BE
- Belgium
- Prior art keywords
- tnf
- aqueous solution
- stabilizing agent
- emi
- activity
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 50
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title claims description 14
- 102000003390 tumor necrosis factor Human genes 0.000 title claims description 14
- 230000000087 stabilizing effect Effects 0.000 title description 15
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 152
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 151
- 230000000694 effects Effects 0.000 claims description 76
- 239000000243 solution Substances 0.000 claims description 57
- 239000003381 stabilizer Substances 0.000 claims description 49
- 239000000843 powder Substances 0.000 claims description 34
- 108010010803 Gelatin Proteins 0.000 claims description 32
- 239000007864 aqueous solution Substances 0.000 claims description 32
- 229920000159 gelatin Polymers 0.000 claims description 32
- 235000019322 gelatine Nutrition 0.000 claims description 32
- 235000011852 gelatine desserts Nutrition 0.000 claims description 32
- 239000008273 gelatin Substances 0.000 claims description 30
- 102000007327 Protamines Human genes 0.000 claims description 27
- 108010007568 Protamines Proteins 0.000 claims description 27
- 229940048914 protamine Drugs 0.000 claims description 22
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 18
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 16
- 102000009027 Albumins Human genes 0.000 claims description 14
- 108010088751 Albumins Proteins 0.000 claims description 14
- 108010044091 Globulins Proteins 0.000 claims description 14
- 102000006395 Globulins Human genes 0.000 claims description 14
- 108010074605 gamma-Globulins Proteins 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 229940041181 antineoplastic drug Drugs 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 238000000338 in vitro Methods 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 239000002158 endotoxin Substances 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 241000124008 Mammalia Species 0.000 description 10
- 206010028851 Necrosis Diseases 0.000 description 10
- 230000017074 necrotic cell death Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- 238000010998 test method Methods 0.000 description 7
- 241000972773 Aulopiformes Species 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 235000019515 salmon Nutrition 0.000 description 6
- 238000007710 freezing Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000010257 thawing Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229950008679 protamine sulfate Drugs 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108090000942 Lactalbumin Proteins 0.000 description 3
- 102000004407 Lactalbumin Human genes 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000002008 hemorrhagic effect Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000252203 Clupea harengus Species 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- 241001464975 Cutibacterium granulosum Species 0.000 description 2
- 229920002271 DEAE-Sepharose Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010088842 Fibrinolysin Proteins 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- 206010054094 Tumour necrosis Diseases 0.000 description 2
- 229920000392 Zymosan Polymers 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000003145 cytotoxic factor Substances 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 229940001501 fibrinolysin Drugs 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000019514 herring Nutrition 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 101100046526 Mus musculus Tnf gene Proteins 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 241000936695 Streptomyces gardneri Species 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 229940070353 protamines Drugs 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 108010033612 venilon Proteins 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57056690A JPS58174330A (ja) | 1982-04-07 | 1982-04-07 | ガン壊死因子の安定化法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE896383A true BE896383A (fr) | 1983-08-01 |
Family
ID=13034438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE0/210494A BE896383A (fr) | 1982-04-07 | 1983-04-06 | Procede pour stabiliser un facteur de necrose tumorale et solution aqueuse ou poudre stables contenant ce facteur |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS58174330A (enrdf_load_stackoverflow) |
| BE (1) | BE896383A (enrdf_load_stackoverflow) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60126217A (ja) * | 1983-12-14 | 1985-07-05 | Sumitomo Chem Co Ltd | 長期徐放性製剤 |
| JP2629000B2 (ja) * | 1986-07-18 | 1997-07-09 | 中外製薬株式会社 | 安定な顆粒球コロニー刺激因子含有製剤 |
| KR900700079A (ko) * | 1988-01-12 | 1990-08-11 | 후지하라 도미오 | 누출방지 리포좀 제제 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55108821A (en) * | 1979-02-14 | 1980-08-21 | Kanebo Ltd | Preparation of antitumor agent |
| JPS5716823A (en) * | 1980-07-03 | 1982-01-28 | Green Cross Corp:The | Live mumps vaccine pharmaceutical and stabilizing method |
-
1982
- 1982-04-07 JP JP57056690A patent/JPS58174330A/ja active Granted
-
1983
- 1983-04-06 BE BE0/210494A patent/BE896383A/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0375529B2 (enrdf_load_stackoverflow) | 1991-12-02 |
| JPS58174330A (ja) | 1983-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH656534A5 (fr) | Procede pour stabiliser un facteur de necrose tumorale et solution aqueuse ou poudre stables contenant ce facteur. | |
| US11458170B2 (en) | Pharmaceutical composition comprising erythrocytes encapsulating a PLP-dependent enzyme and, a non-phosphate PLP precursor | |
| EP2167639B1 (fr) | Milieu de culture pour haemophilus influenzae de type b | |
| EP0035429B1 (fr) | Complexe vaccinal contenant un antigène spécifique et vaccin le contenant | |
| Roberts et al. | New procedures for purification of L-asparaginase with high yield from Escherichia coli | |
| Berry et al. | Bacterial toxins | |
| CH650801A5 (fr) | Procede pour preparer de l'interferon de type ii et preparation contenant de l'interferon de type ii. | |
| CH637831A5 (fr) | Procede de preparation d'interferon et preparation le contenant. | |
| JPH0558000B2 (enrdf_load_stackoverflow) | ||
| JPS5816685A (ja) | 固定化酵素，その製造法および製剤 | |
| Raiha et al. | Effect of ethanol oxidation on levels of pyridine nucleotides in liver and yeast. | |
| Hayano et al. | Streptococcal sialidase I. Isolation and properties of sialidase produced by group K Streptococcus | |
| FR2590172A1 (fr) | Nouvel antigene commun (psc-a) de pseudomonas aeruginosa protegeant contre l'infection provoquee par cet organisme | |
| FR2556220A1 (fr) | Nouveau lymphokine et anticorps monoclonal specifique de ce lymphokine, leur production et leurs utilisations | |
| BE896383A (fr) | Procede pour stabiliser un facteur de necrose tumorale et solution aqueuse ou poudre stables contenant ce facteur | |
| Siard | Queuine metabolism and cadmium toxicity in Drosophila melanogaster | |
| JP3649787B2 (ja) | 魚類の腸球菌感染症用予防剤およびその用途 | |
| BE873594A (fr) | Interferon et preparation le contenant | |
| JPH1070960A (ja) | セレン含有菌体の用途 | |
| EP1244690B1 (fr) | Procede de preparation d'un polypeptide soluble en solvant aqueux en absence de detergent | |
| FR2536281A1 (fr) | Compositions pharmaceutiques permettant de reguler les fonctions phagocytaires | |
| JPS5920225A (ja) | ガン壊死因子の安定化方法 | |
| EP0308475A1 (fr) | Adjuvant de certains antimitotiques chimiques a partir de vibrio cholerae | |
| JPH0567159B2 (enrdf_load_stackoverflow) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE20 | Patent expired |
Owner name: *ASAHI KASEI KOGOYO K.K. Effective date: 20030406 Owner name: *DAINIPPON PHARMACEUTICAL CO. LTD Effective date: 20030406 |